{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:10Z","timestamp":1786119670367,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,15]]},"DOI":"10.1097\/tp.0b013e31820d3b9b","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T01:30:55Z","timestamp":1296783055000},"page":"779-785","source":"Crossref","is-referenced-by-count":25,"title":["Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients"],"prefix":"10.1097","volume":"91","author":[{"given":"Claudia","family":"Sommerer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Glander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Arns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tofan","family":"Ariatabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Shipkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Liefeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Hackenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2215\/CJN.07111009","article-title":"Consensus report on therapeutic drug monitoring of mycophenolic acid on solid organ transplantation.","volume":"5","author":"Kuypers","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R2-14-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","article-title":"Therapeutic drug monitoring of mycophenolate mofetil in transplantation.","volume":"28","author":"van Gelder","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R3-14-20210129","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/TP.0b013e3181744199","article-title":"Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review.","volume":"85","author":"Knight","year":"2008","journal-title":"Transplantation"},{"key":"R4-14-20210129","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2215\/CJN.02860806","article-title":"Therapeutic monitoring of mycophenolate mofetil.","volume":"2","author":"Jeong","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R5-14-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R6-14-20210129","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"},{"key":"R7-14-20210129","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","article-title":"Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial.","volume":"86","author":"van Gelder","year":"2008","journal-title":"Transplantation"},{"key":"R8-14-20210129","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00007691-200310000-00011","article-title":"Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.","volume":"25","author":"Kuypers","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R9-14-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","article-title":"A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.","volume":"68","author":"van Gelder","year":"1999","journal-title":"Transplantation"},{"key":"R10-14-20210129","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2004.00455.x","article-title":"Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation.","volume":"4","author":"Kiberd","year":"2004","journal-title":"Am J Transplant"},{"key":"R11-14-20210129","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy.","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-14-20210129","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2215\/CJN.06050809","article-title":"Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.","volume":"5","author":"Glander","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-14-20210129","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2215\/CJN.09091209","article-title":"The CLEAR Study: A 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.","volume":"5","author":"Gourishankar","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R14-14-20210129","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2125.2009.03612.x","article-title":"Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: Limited sampling strategies and clinical outcome in renal transplant patients.","volume":"69","author":"Sommerer","year":"2010","journal-title":"Br J Clin Pharm"},{"key":"R15-14-20210129","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","article-title":"Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The Opticept trial.","volume":"9","author":"Gaston","year":"2009","journal-title":"Am J Transplant"},{"key":"R16-14-20210129","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/FTD.0b013e3181b8679a","article-title":"Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium.","volume":"3","author":"De Winter","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R17-14-20210129","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.","volume":"10","author":"Tedesco-Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"R18-14-20210129","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"R19-14-20210129","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1600-6143.2007.01661.x","article-title":"One-year results with extended release tacrolimus\/MMF, tacrolimus\/MMF and cyclosporine\/MMF in de novo kidney transplant recipients.","volume":"7","author":"Silva","year":"2007","journal-title":"Am J Transplant"},{"key":"R20-14-20210129","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R22-14-20210129","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1600-6143.2010.03053.x","article-title":"T cell-mediated rejection of kidney transplants: A personal viewpoint.","volume":"10","author":"Halloran","year":"2010","journal-title":"Am J Transplant"},{"key":"R23-14-20210129","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/ndt\/gfp162","article-title":"The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: The Symphony pharmacokinetic substudy.","volume":"24","author":"Griny\u00f3","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R24-14-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R25-14-20210129","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/j.1600-6143.2004.00585.x","article-title":"Banff 2003 meeting report: New diagnostic insights and standards.","volume":"4","author":"Racusen","year":"2004","journal-title":"Am J Transplant"},{"key":"R26-14-20210129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS \u2014A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease.","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig Dis Sci"},{"key":"R27-14-20210129","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1477-7525-1-62","article-title":"Psychometric validation of the German translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in patients with reflux disease.","volume":"1","author":"Kulich","year":"2003","journal-title":"Health Qual Life Outcomes"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-201104150-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:51:24Z","timestamp":1786042284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-201104150-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,15]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e31820d3b9b","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,15]]}}}